Lifesci Capital Issues Negative Outlook for DNTH Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Analysts at Lifesci Capital reduced their Q3 2025 earnings per share estimates for Dianthus Therapeutics in a report released on Wednesday, August 13th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings of ($0.88) per share for the quarter, down from their prior estimate of ($0.87). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. Lifesci Capital also issued estimates for Dianthus Therapeutics’ Q4 2025 earnings at ($0.90) EPS and FY2025 earnings at ($3.49) EPS.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.

Several other equities analysts have also commented on the company. Robert W. Baird decreased their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an “outperform” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $53.00.

Dianthus Therapeutics Stock Up 2.4%

Shares of Dianthus Therapeutics stock opened at $20.74 on Friday. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $32.27. The business’s fifty day simple moving average is $19.49 and its 200-day simple moving average is $20.00. The firm has a market cap of $667.62 million, a PE ratio of -6.38 and a beta of 1.43.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at $27,000. US Bancorp DE raised its holdings in shares of Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock valued at $29,000 after buying an additional 1,510 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at $59,000. GAMMA Investing LLC raised its holdings in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after buying an additional 3,758 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after buying an additional 3,317 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.